Updated COVID-19 vaccines from Moderna, Pfizer, and Novavax have received FDA approval for the 2025 season. Health and Human Services Secretary Robert F. Kennedy Jr. confirmed the announcement on August 27, noting that emergency-use authorizations have ended.
The updated vaccines will now be recommended only for those at high risk.
Who Is Eligible Under New Guidelines
Federal recommendations limit vaccines to adults 65 and older and individuals with underlying health conditions. This marks a major shift from previous CDC guidance, which advised vaccination for everyone six months and older. Pregnant women and healthy children are no longer included in the national immunization schedule.
Are Vaccines Being Banned?
Despite concerns, federal officials insist vaccines are not being banned. The White House called rumors of prohibition “baseless speculation.” Instead, vaccines are transitioning to the traditional approval pathway, meaning they remain available but will be marketed and distributed under stricter guidelines than during the emergency-use phase.
Impact on Access and Insurance
Experts warn that access could become more difficult for many Americans. Insurance companies generally follow federal recommendations, meaning individuals under 65 without high-risk conditions may face out-of-pocket costs.
While vaccines are not removed from the market, financial barriers may discourage uptake in younger and healthier populations.
Details on Approved Vaccines
Pfizer’s updated vaccine is approved for adults 65 and older, as well as children over 5 with at least one qualifying health condition. Moderna’s updated Spikevax is authorized for people 65 and older and for those 6 months or older with a high-risk condition.
Moderna also introduced a new formula, mNEXSPIKE, approved for individuals 12 and older with an underlying condition, in addition to everyone over 65. Novavax’s vaccine received approval for the same high-risk groups, providing an alternative for those who prefer non-mRNA immunizations.
Federal Clarifications on Policy
In a Q&A, HHS emphasized the transition reflects a move away from dual pathways — emergency-use and traditional approval — to a single, permanent approval framework. Officials stressed that “this is not a removal of COVID-19 vaccines from the market,” but acknowledged access will depend more heavily on medical consultation.
Access in North Carolina
In North Carolina, vaccines are available through doctors, local health departments, and some pharmacies. The state’s Department of Health and Human Services (NCDHHS). Residents are encouraged to confirm availability with providers before scheduling appointments.
Cost and Assistance Programs
Under the new system, individuals under 65 who are not classified as high-risk may need to pay out of pocket for vaccination. NCDHHS offers assistance programs for uninsured residents.
COVID-19 Testing in North Carolina
Testing options remain widely available. Residents can purchase home tests from pharmacies or online retailers. Additionally, doctors, pharmacies, tribal health centers, and community clinics may provide testing.
Broader Implications for Public Health
The narrowed federal recommendations reflect a significant policy change, shifting responsibility for vaccine access away from universal guidance toward a more targeted, risk-based model.
While officials maintain vaccines remain accessible, public health experts caution that reduced coverage could lead to lower vaccination rates and greater vulnerability during seasonal surges.
Looking Ahead
As the fall and winter respiratory season approaches, healthcare providers are expected to play a larger role in guiding vaccine decisions.
Public health officials urge those at risk — including seniors and people with chronic conditions — to seek vaccination promptly, while others should consult their providers about personal risk factors.
